If you have any questions for next week's webinar guest speakers (Pyx Resources, Helix Exploration, Fulcrum Metals and Metals One), please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.80
Bid: 12.60
Ask: 13.00
Change: -0.30 (-2.33%)
Spread: 0.40 (3.175%)
Open: 12.90
High: 12.60
Low: 12.60
Prev. Close: 12.90
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Poolbeg Pharma hails POLB 001'S potential to treat CRS

Wed, 17th Jan 2024 13:58

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Poolbeg is a London-based clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need.

POLB 001 is a bacterial lipopolysaccharide treatment being developed to "address the significant unmet medical need for severe influenza."

A recent LPS human challenge trial, which evaluated the effect of POLB 001 on inflammatory responses in 36 healthy volunteers aged between 18 and 55, showed that the treatment was well tolerated, with no serious adverse effects or volunteer withdrawals.

The results, together with data from the recent challenge trial, support Poolbeg's "strategic expansion of the Phase II ready POLB 001 to treat and prevent cancer immunotherapy-induced CRS," it said. The data also strengthens and facilitates the expansion of patent applications for POLB 001.

According to the American Cancer Society, there will be approximately 24.6 million cases of cancer by 2030. Poolbeg said the cancer immunotherapy market is estimated at around USD1 billion.

Poolbeg Chief Business Officer David Allmond said: "POLB 001 has the potential to revolutionise the impact of cancer immunotherapies by enabling safer and broader use in an outpatient setting, reducing healthcare resource utilisation and making these next generation cancer treatments more widely available to the patients that need them. The pharmaceutical sector is seeking an effective solution for CRS and, as an oral therapy, we believe there is a significant opportunity for POLB 001 to meet this critical unmet medical need and have a positive impact on global health."

Shares in Poolbeg were up 3.3% at 9.04 pence each in London on Wednesday afternoon.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
6 Jun 2024 14:52

UK shareholder meetings calendar - next 7 days

Friday 7 June 
Property Franchise Group PLCAGM
Trident Royalties PLCAGM
TruSpine Technologies PLCAGM
Monday 10 June 
Aterian PLCAGM
Griffin Mining LtdAGM
Lok'n Store Group PLCGM re takeover by Shurgard
Onward Opportunities LtdAGM
Oxford Nanopore Technologies PLCAGM
Pan African Resources PLCGM re capital reduction
Tuesday 11 June 
Ebiquity PLCAGM
Flowtech Fluidpower PLCAGM
MaxCyte IncAGM
Mobico Group PLCAGM
Newbury Racecourse PLCAGM
Nightcap PLCGM re fundraise
Phoenix Digital Assets PLCGM re up to GBP33.7 million fundraise
Tirupati Graphite PLCGM requisitioned by Walpole St Andrews Nominees
Tortilla Mexican Grill PLCAGM
Tufton Oceanic Assets LtdEGM
Wednesday 12 June 
Advanced Medical Solutions Group PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Aurora Investment Trust PLCAGM
BioPharma Credit PLCAGM
Brighton Pier Group PLCAGM
Digital 9 Infrastructure PLCAGM
EPE Special Opportunities LtdAGM
Foresight Solar Fund LtdAGM
Star Energy Group PLCAGM
Thursday 13 June 
Beacon Rise Holdings PLCAGM
Christie Group PLCAGM
Everyman Media Group PLCAGM
Hochschild Mining PLCAGM
Iofina PLCAGM
Jadestone Energy PLCAGM
Panther Metals PLCAGM
Pollen Street Group LtdAGM
Poolbeg Pharma PLCAGM
Serabi Gold PLCAGM
Smurfit Kappa Group PLCGM re WestRock deal
Sound Energy PLCAGM
Starwood European Real Estate Finance LtdAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
1 May 2024 16:39

Poolbeg Pharma celebrates full patent approval for Immunomodulator II

(Alliance News) - Poolbeg Pharma PLC on Wednesday said that it has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Read more
30 Apr 2024 16:43

Poolbeg agrees 12-month option over potential Behcet's treatment

(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Read more
30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.